Human Genetic Therapies Boosts Shire, Thanks To Replagal Growth
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme's inability to provide Fabry disease patients with Fabrazyme has created an opening for Replagal, whose half-year sales are up 77 percent year-over-year.